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INTERSTITIAL LASER COAGULATION FOR BENIGN 
PROST A TIC HYPERPLASIA: CLINICAL RESUL TS 
OF THE INDIGO DIODE LASER SYSTEM 
Yosuke MATSUTA， Kentaro ICHIOKA， Naoki TERADA， Shinya MAEKAWA， 
Kazutoshi OKUBO， Koji YOSHIM目 A，Akito TERAI and Y oichi ARAI 
From the Dψartment 01 Urology， Kurashiki Central Hospital 
We report our experience with interstitiallaser coagulation ofthe prostate (ILCP) using an Indigo 
830{M diode laser system for benign prostatic hyperplasia (BPH). 
From March 1998 to November 2000， we treated 45 patients between 51 and 95 years old (average 
71.5) with symptomatic BPH. The mean prostatic volume before ILCP was 62.0 cm3 We 
experienced no serious complications. Three months after ILCP， the mean international prostate 
symptom score (I-PSS) quality of life (QOL) index and post-void residual volume (PVR) decreased 
significantly from 18.0 to 9.2， from 4.4 to 2.1 and from 103.6 ml to 44.5 ml， respectively. The mean 
maximum flow rate (MFR) increased from 7.6 ml/sec at baseline to 9.2 ml/sec 3 months after ILCP， 
but the difference was not statistically significant. Before and after ILCP， 8 patients were available to 
evaluate pressure-flow study data. The detrusor pressure at the maximum flow rate decreased 
significantly from 118.3 cmH20 at baseline to 78.6 cmH20 3 months a丘町 ILCP. The improvement 
ofthe I-PSS， QOL index， MFR and PVR continued and at 24 months reached 5.7，1.8，11.6 ml/sec and 
54.6 ml， respectively. In our assessment ofthe questionnaire addressing the patient's satisfaction after 
the treatment， the majority of the patients who answered the questionnaire were pleased with the 
results of ILCP. We assessed the relation of the overall treatment efficacy with the number of 
punctures and the total amount of the laser energy delivered， but we did not find any relation. 
Our clinical results suggest that the ILCP using Indigo 830{M is an effective modality and the 
short-term treatment efficacy is favorable. 
(Acta Urol. Jpn. 49: 195-200， 2003) 
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緒 広司
前立腺肥大症に対する手術治療としては， trans-






近年 minimalinvasive surgerγ の概念に基づく
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transurethral needle ablation (TUNA)， transure-
thral microwave thermotherapy (TUMT)などの治
療法が紹介され，その治療成績についての報告がなさ
れている.その一つである interstitiallaser coagula-































34 (18.0土8.0)，QOL indexは2-6 (4.4士1.2)， 
前立腺体積は 25.0-135.8cm3 (62.0士27.2cm3) ， 
最大尿流量率は1.1-15.0m1/sec (7.6士3.8m1/sec)， 






















ワーキングチャンネルを持つ 21Frのもの， 300 のも
のを使用した産流液は生理食塩水を使用したが，
Table 1. Questionnaire for assessing satis-




































































QOL index (0-6) 
mean土S.D. 4.4土1.2






























Post-void residual volume (ml) 
mean:tS.D. 103.6土114.2 67.6:t64.4 


































後 iカ月で 7例， 3カ月で 3例であった. CIC期間
が遷延した 3症例のうち 2例 (4.4%)は排尿障害が
改善せず追加治療を要し，いずれも TURPが施行さ
Wilcoxon signed胆rankstest;不:p<0.05， *本p<O.OI，料*: p<O.OOI， **** : p<O.OOOI. 





















Wilcoxon signed-ranks test 
Sequential changes in detrusor pres-
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Sequential changes in overall treatment efficacy Table 3 




































198 泌尿紀要 49巻 4号 2003年
Table 4. Comparison of pre-treatment parameters between Good responders and poor responders (3 
months after ILCP) 
Good responders (1e3 xcellent，good) Poor r凶ponders(fair， poor/worse) 
n= n=18 Mann-Whitney's U test 
mean土S.D. mean:lS.D 
Age (years old) 69.2土 8.7 74.7土 7.4 p=0.0712 
IPSS 20.4士 6.9 15.6士 7.8 N.S. 
QOL score 4.8:1 0.6 3.9士1.3 p<0.05 
MFR (ml/s) 7.2土 3.0 7.6士 4.0 N.S. 
PVR(ml) 103.8土88.4 113.3士151.3 N.S. 
PV (cm3) 58.6:120.5 62.0土 29.2 N.S. 
TZV (cm3) 44.4:1:21.3 43.4土 29.1 N.S. 
Table 5. Overall treatment efficacy and number of punctures， laser energy delivery 
Good responders 
(EXCElnle=nt1，3 good) Poor proESoDr/owndo Ers (fair， poor/worse) 
No. punctures/prostate 
Prostate volume/puncture (cm3) 
TZ volume/pur凶 ure(cm3) 
Laser energy delivery/prostate (kJ) 
Prostate volume/energy delivery (cm3 IkJ) 









比較して年齢が高く (74.3:18.8歳 vs70.7:1 10.1歳入

















センサーを搭載し， tissue adaptive modeを利用する
ことで治療中の温度コントロールが可能であり，他の
機種と比較して安全性が高いと考えられる.
われわれの治療経過の検討により， Indigo 830jTM 
を用いた ILCPにより IPSSや QOLindexに表さ
れる自覚症状の改善のみならず，他覚所見としての残
尿量の減少がえられることが確認された.最大尿流量
n=18 Mann-Whitney's U test 
mean士S.D.
7.9:!:3.6 N.S. 
8.0:1 1.5 N.S. 
5.2士1.7 N.S. 
10.0士4.2 N.S. 









































































治療 1，3， 6， 12， 18カ月後および24カ月後，でそ
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